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Protocol
AbstrACt
Introduction Cardiac rehabilitation (CR) reduces all-cause 
and cardiovascular mortality in patients with coronary 
heart disease (CHD). Much of this improvement has been 
attributed to the beneficial effects of structured exercise 
training. However, UK-based studies have not confirmed 
this. Improvements in survival and cardiovascular 
health are associated with concurrent improvements in 
cardiorespiratory fitness (CRF). It is therefore concerning 
that estimated CRF improvements resulting from UK-
based CR are approximately one-third of those reported 
in international literature. Modest improvements in 
CRF suggest that UK CR exercise training programmes 
may require optimisation if long-term survival is to be 
improved. However, contemporary UK studies lack control 
data or use estimates of CRF change. Cardiovascular 
and cardiorespiratory Adaptations to Routine Exercise-
based CR is a longitudinal, observational, controlled study 
designed to assess the short-term and long-term effect 
of CR on CRF, as well cardiovascular and cardiometabolic 
health.
Methods and analysis Patients will be recruited following 
referral to their local CR programme and will either 
participate in a routine, low-to-moderate intensity, 8-week 
(16 sessions) exercise-based CR programme or freely 
abstain from supervised exercise. Initial assessment will 
be conducted prior to exercise training, or approximately 
2 weeks after referral to CR if exercise training is declined. 
Reassessment will coincide with completion of exercise 
training or 10 weeks after initial assessment for control 
participants. Participants will receive a final follow-up 
12 months after recruitment. The primary outcome will 
be peak oxygen consumption determined using maximal 
cardiopulmonary exercise testing. Secondary outcomes 
will include changes in subclinical atherosclerosis (carotid 
intima–media thickness and plaque characteristics), 
body composition (dual X-ray absorptiometry) and 
cardiometabolic biomarkers.
Ethics and dissemination Ethical approval for this 
non-randomised controlled study has been obtained from 
the Humber Bridge NHS Research Ethics Committee—
Yorkshire and the Humber on the 27th September 2013, 
(12/YH/0278). Results will be presented at national 
conferences and published in peer-reviewed journals.
IntroduCtIon 
Coronary heart disease (CHD) affects 
2.3 million people in the UK and is a leading 
cause of premature death.1 Improvements 
in diagnosis and medical treatment have 
resulted in improved survival rates, however, 
the burden of CHD remains a major public 
health challenge. Cardiac rehabilitation (CR) 
is a comprehensive programme of secondary 
prevention measures that has been shown to 
have significant health benefits for patients 
with CHD.
The aim of CR is to increase survival, 
reduce cardiovascular disease (CVD)-related 
morbidity and hospital admissions, improve 
strengths and limitations of this study
 ► The use of ‘gold-standard’ maximal cardiopulmonary 
exercise testing will provide some of the most 
accurate and objective cardiorespiratory fitness 
outcomes derived from UK cardiac rehabilitation 
(CR) data.
 ► Carotid intima–media thickness measurements 
will demonstrate the effect of CR on atherosclerotic 
disease progression.
 ► The observational nature of this study 
conducted  within local CR ensures ecological 
validity of our findings.
 ► The non-randomised nature of this study may result 
in group allocation bias.
 ► This is a single-centre study with participant referral/
recruitment constraints that are characteristic of 
exercise training within UK-based CR.
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functional capacity, quality of life and facilitate early 
return to work.2 3 This is achieved through structured 
exercise training and increasing physical activity, preven-
tive medical therapies, education and behaviour change, 
counselling support and other cardiovascular risk factor 
reduction strategies.2 4 Although variations in service 
provision exist across the UK,5 CR exercise training 
is usually offered in the early postadmission period 
following a cardiac event. The UK healthcare system no 
longer uses ‘Phases’ to describe CR, however, early post-
admission supervised exercise training may be equated to 
Phase III CR.
Structured exercise training is one of the primary 
components of CR2 6 7 and may make the largest contri-
bution to increasing patient survival.8 9 Exercise training 
alone is associated with a 28% all-cause mortality reduc-
tion.10 Contemporary evidence suggests that all-cause and 
CVD mortality, recurrent cardiac events,11 and hospital 
admissions are reduced while quality of life is improved.9 
However, a recent Cochrane review questioned these find-
ings and reported that CVD mortality (10.4% to 7.6%) 
but not all-cause mortality was reduced following CR.9 12
Contradictory to consecutive meta-analyses,9 11 13 
UK-derived data suggest that CR may not improve CVD or 
all-cause mortality.14–16 The most recent UK randomised 
controlled study reported no survival benefit,16 though 
did not consider cardiorespiratory fitness (CRF) changes. 
Peak oxygen uptake (VO2peak) (determined during maximal 
cardiopulmonary exercise testing (CPET)17 is used to 
quantify CRF. VO2peak is inversely associated with all-cause 
and cardiovascular mortality in patients with CHD.18 19 
A 1% improvement in VO2peak following 3 months exer-
cise training confers a 2% reduction in cardiovascular 
mortality20 with the least fit patients showing the greatest 
survival advantage from any improvements.21 22 However, 
a dose–response relationship between the amount of 
exercise training undertaken and increase in VO2peak may 
exist.20
UK clinical trial data23 in patients who sustained 
a myocardial infarction (MI), reported increases 
in VO2peak following 12 months supervised exercise 
training compared with controls. However, a recent 
multicentre study of routine UK-based CR (current clin-
ical practice) indicates that the ‘exercise dose’ within 
outpatient CR may be insufficient to meaningfully 
improve CRF24 25 (˜0.5 metabolic equivalents [METs]; 
or VO2 1.75 mL/kg/min) when compared with inter-
national programmes (˜1.5 METs; or VO2 5.25 mL/
kg/min).26 Fewer than 50% of patients completing a 
‘typical’ UK CR programme may achieve minimal clin-
ically important improvements to CRF, (70 m) derived 
from incremental shuttle walk testing.27 These findings 
may explain why UK CR programmes do not appear to 
improve patient survival.14–16 However, UK studies typi-
cally estimate CRF changes from submaximal exercise 
testing protocols. This may lead to inaccurate reporting 
of VO2peak changes following CR in patients with CHD.
28 
There is a need to investigate the exercise-based CR 
findings of Sandercock et al29 using ‘gold-standard’ 
CPET testing methods.
Numerous mechanisms may be responsible for 
improving survival associated with exercise-based CR 
and improved CRF, including cardiovascular risk factor 
modification (smoking, lipids, blood pressure (BP), 
glucose metabolism). Within one meta-analysis, approx-
imately half of the 28% reduction in cardiac mortality 
achieved with exercise-based CR was attributed to reduc-
tions in major cardiovascular risk factors, particularly 
reduced smoking.9 Anti-ischaemic/thrombotic effects, 
cardiac remodelling, and antiatherosclerotic and vascular 
conditioning have also been documented.30 31 Larger 
volumes of exercise training (associated with higher 
energy expenditures) have been shown to underline 
regression of atherosclerosis.32 Carotid intima–media 
thickness (C-IMT) is a practical, valid and reliable non-in-
vasive surrogate marker of subclinical atherosclerosis.33–35 
Carotid ultrasound has been used to non-invasively char-
acterise dynamic changes in atherosclerotic plaque char-
acteristics. While some data suggest that exercise training 
may reduce C-IMT in patients at elevated CV risk,36 37 the 
evidence is still unclear.38 Furthermore, no UK study has 
investigated the effects of a short-term, routine CR exer-
cise training programme on longer-term atherosclerotic 
disease progression. The modest improvements in CRF 
reported within UK CR patients,29 39 and the reported 
absence of improved survival outcomes, may indicate 
that the exercise dose prescribed to patients is too low to 
meaningfully influence CRF, cardiometabolic risk factors 
and atherosclerotic plaque progression. Therefore, the 
objectives of this controlled trial are:
To determine, when compared with CR without exer-
cise training, the short-term (8-week) and long-term 
(12-month) effects of a routine, 8 week, low-to-moderate 
intensity UK CR exercise training programme on:
1. Changes in VO2peak assessed using ‘gold-standard’ 
CPET.
2. Subclinical and clinical atherosclerosis progression 
using C-IMT measurements.
3. Standard risk factors including lipid profiles, BP and 
blood glucose, measurement, and cardiometabolic 
markers including N-terminal pro-brain natriuretic 
peptide (NT-proBNP) and high-sensitivity C-reactive 
protein (hs-CRP).
4. Estimated all-cause 5-year mortality risk using the 
comprehensive CALIBER score.40
MEthods
study design
This study will be a pragmatic, single-centre longitu-
dinal controlled study of a routine National Health 
Service (NHS) outpatient CR programme. Patients 
recruited to the study will have the option to attend a 
routine low-to-moderate intensity, 8-week circuit-based 
CR exercise training programme (routine CR) or volun-
tarily abstain (control group (CG)) from the structured 
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exercise training component of the CR programme. 
Study measures will be made before starting exercise 
training or approximately 2 weeks after recruitment for 
patients who decline the exercise programme (visit 1). 
Follow-up assessment will be conducted after completion 
of a patients CR programme (visit 2) or approximately 10 
weeks after recruitment for controls. The difference in 
planned reassessment times accounts for a typical 2-week 
waiting time to receive NHS treatment (exercise training) 
at this centre, and will allow both groups to be reassessed 
within a similar timeframe. Patients will also be invited for 
assessment 12 months after visit 1 (visit 3).
Routine CR will be delivered by clinical (not research) 
staff within existing NHS secondary prevention care path-
ways. The study will be conducted in collaboration with 
Hull’s CR team (City Healthcare Partnership CIC) who 
follow the Department of Health41 ‘best care pathway’ for 
referral and delivery of CR. Adherence to national guide-
lines on exercise prescription will allow broad generalis-
ability of the findings to UK-based CR programmes. The 
trial protocol adheres to the Standard Protocol Items: 
Recommendations for Clinical Trials guidelines.
setting
Patients can attend CR at three sites across Hull: The 
University of Hull (West Hull), Hull Royal Infirmary (Hull 
Centre) and the Freedom Centre (Community Centre, 
East Hull). Testing will be conducted at the Academic 
Cardiology Research Laboratory at Castle Hill Hospital, 
Hull.
Participants
Patients who have had a recent hospital admission for 
stable angina, MI (ST-Elevation or non ST-elevationMI 
and non-STEMI), coronary artery bypass graft (CABG) 
surgery, and elective percutaneous coronary interven-
tion (PCI) will be recruited recruitment by a specialist 
CR nurse, typically within 2 weeks of sustaining a cardiac 
event. Patients will be offered all CR secondary preven-
tion components recommended by the British Associa-
tion for Cardiovascular Prevention and Rehabilitation 
(BACPR),2 including exercise training. Those opting to 
take part in structured, supervised exercise training will 
be referred to as the treatment group (TG). Those who 
decline exercise training will be known as the control 
group (CG). Group randomisation will not be performed 
as this is deemed unethical given the current evidence 
for the benefits of exercise-based CR.9 Patients in both 
groups will be advised to increase unsupervised physical 
activity levels.
General inclusion criteria
1. Primary diagnosis of CHD including recent MI, CABG 
surgery, elective PCI or exertional angina.
2. Clinically stable patients.
3. Aged 30–85 years.
4. Absence of contraindications to exercise testing and 
exercise training.
5. Capable and mentally able to understand and follow 
the instructions of the health professional team.
General exclusion criteria
1. Clinically unstable patients.
2. Clinically significant valvular heart disease.
3. Patients with a non-ischaemic diagnosis.
4. Patients with coexisting congenital heart condi-
tions, significant comorbidities including severe 
chronic heart failure  (left ventricular ejection frac-
tion (LVEF)  <30%), advanced cancer and conditions 
preventing the patient from providing informed con-
sent.
5. Current drug abusers and excessive alcohol drinkers.
6. Patients not freely living in the community, such as 
those currently serving a custodial sentence
7. Patients unwilling or unable to participate in key as-
pects of the study.
8. Patients with ongoing clinical complications, open 
wounds or systemic infections.
9. Women who are pregnant or breast feeding.
A study flow diagram is presented in figure 1. Patients 
will be referred to CR via the local tertiary hospital (Castle 
Hill Hospital, Hull) where they will receive a one-to-one 
assessment with a CR specialist nurse. Nursing staff will 
provide patients with information on cardiac medica-
tions, diet, smoking cessation, physical activity, structured 
exercise training and other secondary prevention meas-
ures. Eligible patients will be offered the opportunity to 
participate in this study. Group specific patient informa-
tion sheets will be provided.
Written informed consent will be obtained by a medical 
doctor at the Academic Cardiology Research Labora-
tory, Castle Hill Hospital, Hull. Patients will be asked to 
attend in a euhydrated state and having not conducted 
strenuous exercise within the previous 24 hours. Patients 
will not fast prior to any visit due to the need to conduct 
maximal CPET at the end of the 4-hour visit. Patients will 
be advised to eat a light meal prior to each visit.
A resting ECG, echocardiogram, venepuncture, carotid 
ultrasound (C-IMT) and dual X-ray absorptiometry 
(DXA) will be performed at each visit. A CPET to voli-
tional exhaustion or clinically relevant symptoms42 will 
be conducted after all other investigations have been 
completed. Patients will then follow their chosen treat-
ment plan (treatment or control). All measurements 
taken at visit 1 will be repeated at visit 2 and 3. At visit 2 and 
3, all patients will be asked to verbally report the typical 
number of structured exercise sessions they engaged in 
during the previous week, as well as how many minutes 
each of those session lasted. This will allow a comparison 
of exercise dose between both groups. Adverse events will 
be reported in accordance with NHS good clinical prac-
tice guidelines.
Anthropometry and resting haemodynamic measurements
Patients will be instructed to remove footwear, jackets and 
items from their pockets prior to standing in the centre 
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Figure 1 Study flow diagram. C-IMT, carotid intima–media thickness; CPET, cardiopulmonary exercise testing; CR, cardiac 
rehabilitation; DXA, dual X-ray absorptiometry. 
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of the scales. Body mass (kilograms) will be measured 
using a Tanita Body Composition Analyser MC—180 MA 
(Tanita, Amsterdam, The Netherlands) and recorded to 
one decimal place. Stature (centimetre) will be measured 
(Leicester Height Measure, SECA, Birmingham, UK) 
with patients positioned in the Frankfort plane and their 
heels and head positioned to the back of the stadiometer. 
The highest measurement recorded during a single full 
in-breath will be taken as the individual’s height. Body 
mass index (BMI) will reported as kg.m2, where kg is a 
patients’ body mass and m2 is height squared.
A single waist and hip circumference measurements 
will be taken 1 cm above the iliac crest, and from the 
widest aspect of the buttocks using an inflexible tape. 
Both measurements will be recorded in centimetre and 
the waist-to-hip circumference ratio (waist/hip) will be 
reported.43
Patients will rest for 15 min in a semisupine position 
on an examination bed. A 12-lead ECG (GE Healthcare, 
Buckinghamshire, UK) and left arm brachial BP will be 
recorded using an ECG-gated automated BP cuff (Tango, 
SunTech Medical, Eynsham, UK). Resting HR and BP will 
be recorded following the 15-min rest period.
Cardiopulmonary exercise testing
Respiratory gas exchange data will be collected using 
an Oxycon Pro (Jaeger, Hochberg, Germany) breath-by-
breath metabolic cart. Calibration to ambient tempera-
ture, humidity, altitude and barometric pressure will be 
performed. Gas flow–volume will be calibrated using a 
3 L syringe and will be repeated on at least two occasions. 
Offset values are automatically calculated for accurate 
measurement of ventilatory volumes. Two-point calibra-
tion, using known gas concentrations, will be performed 
to allow accurate quantification of inspired O2 and 
expired CO2 concentrations (control gases: O2 16.4%; 
CO2 4.5%). The 12-lead ECG will be measured continu-
ously throughout the CPET. An ECG-gated automated 
BP will be monitored from the start of CPET and at the 
second minute of each exercise test stage until the end 
of the test.
CPET will be conducted according to international 
recommendations.42 44–46 A description of the CPET 
protocol, Borg's rating of percieved exersion (RPE) 
scale, potential adverse symptoms and CPET stop 
procedures will be given to participants. The modified 
Bruce protocol47 will be used for all CPETs (table 1).
Exercise tests will be preceded by a 3-min seated rest 
period to record pretest gas exchange, BP and HR values. 
Patients will undertake CPET on a treadmill (General 
Electric driven by a GE case system (GE Healthcare, 
Buckinghamshire, UK). Ventilatory expired gases will be 
collected continuously during the rest period, exercise 
and a 6-min recovery period. Talking during CPET will be 
discouraged with the exception of reporting symptoms, 
asking to stop exercise and to provide serial RPE scores.
HR, RPE and estimated arterial oxygen saturation 
(SpO2) will be obtained after 2.5 min of each test stage, at 
peak exercise and during the recovery period. Criteria for 
termination for CPET are displayed in box 1.40
Data will be saved and exported for offline analysis. Data 
will be exported in 30 s, 15 s and middle 5 of 7, breath-by-
breath averages. Table 2 provides a list of traditional and 
novel CPET variables.
The primary outcome measure will be the change in 
VO2peak (mean VO2 over final 30 s of a CPET). Secondary 
CRF outcome measures, including the ventilatory anaer-
obic threshold (VAT), VE/VCO2 slope, peak O2 pulse 
(O2/HR), O2 uptake efficiency slope and, O 2 uptake effi-
ciency plateau will be assessed.
spirometry
Resting spirometry will be conducted using an Oxycon 
Pro. Patients will breathe into a mouth piece connected to 
the respiratory flow turbine of the metabolic cart. Patients 
will be instructed to breathe normally during resting tidal 
volume measurements (litres). Ten full breathing cycles 
will be observed to allow normalisation of the breathing 
pattern. Flow-volume loops will be conducted to obtain 
forced spirometry measurements. Demonstration and 
instruction will be given prior to patients attempting 
the manoeuvre. Up to eight flow-volume loops will be 
conducted to obtain three high-quality manoeuvres. 
Acceptable reproducibility will be defined as ≤0.150 L 
difference between the largest and second largest forced 
Table 1 The modified Bruce protocol
Stage Speed (mph) Gradient (%)
0 1.7 0
1 1.7 5
2 1.7 10
3 2.5 12
4 3.4 14
5 4.2 16
6 5.0 18
box 1 Exercise test termination criteria
 ► Indications for exercise test termination
 ► Chest pain suggestive ischaemia
 ► Ischaemic ECG changes (>2 mm ST segment depression)
 ► Complex ventricular ectopy
 ► Second or third degree heart block
 ► Fall in systolic pressure 20 mm Hg from highest value during the test
 ► Hypertension (250 mm Hg systolic; 120 mm Hg diastolic)
 ► Severe oxygen desaturation: SpO2 less than 80% when accompanied 
by symptoms and signs of severe hypoxaemia
 ► Sudden pallor
 ► Loss of coordination
 ► Mental confusion
 ► Dizziness or faintness
 ► Signs of respiratory distress
SpO2, peripheral capillary O2 saturation.
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expiratory volume in 1 s (FEV1) and forced vital capacity 
(FVC) measurements.48 FEV1, FVC and peak expiratory 
flow will be recorded. Maximum voluntary ventilation will 
be estimated using the calculation FEV1x40.
49–51
dXA scan
Body composition will be analysed using DXA (Lunar 
iDXA, GE Healthcare, Buckinghamshire, UK). Body 
composition analysis will be performed by the Lunar 
iDXA’s integrated software. Total body mass, total body 
fat, compartmental body fat, lean body mass and compart-
mental lean body mass will be recorded for this study. 
Total body mass will be used for the calculation of BMI.
Echocardiogram
A trained echocardiograph technician will conduct each 
echocardiogram. Standard echocardiogram techniques 
will be used including 2D, M-mode, pulse wave Doppler 
to assess cardiac structure and function (systolic and 
diastolic). Left ventricular function will be determined 
from 2D echocardiography. Left ventricular function will 
be assessed by estimation on a catagorical scale of normal, 
mild, mild-to-moderate, moderate, moderate-to-severe 
and severe. Left ventricular ejection fraction (LVEF) will 
be calculated using the Simpson’s formula from measure-
ments of end-diastolic and end-systolic volumes on apical 
4-chamber and 2-chamber views, following the guide-
lines of Schiller et al.52 Left ventricular systolic dysfunc-
tion (LVSD) will be diagnosed if LVEF is ≤45%. When 
LVEF cannot be calculated, LVSD will be diagnosed 
were LVEF ≤45 or there is at least ‘mild-to-moderate’ 
impairment.
Carotid intima–media thickness
C-IMT will be measured using an automated ultra-
sound system (Panasonic CardioHealth Station, 
Table 2 Cardiopulmonary exercise test variables 
Variable Definition Significance
Peak oxygen 
uptake (VO2peak)
Mean VO2 over the last 30 s of CPET
Reported in raw units (mL), adjusted for 
body mass (mL/kg/min) and lean body mass 
determined using DXA (mL/kg/min)
Traditional definition of peak aerobic fitness and limit of 
cardiovascular function
Indicative of cardiovascular disease severity, universal 
prognosticator
Abnormal when below 85% of the predicted value
Ventilatory 
anaerobic 
threshold (VAT)
Determined using the V-slope method using 
the middle 5 of 7 breath data averaging.
Reported in raw units (mL), adjusted for 
body mass (mL/kg/.min) and lean body mass 
determined using DXA (mL/kg/.min).
Represents the point above which, further increments in 
work rate are increasingly sustained through anaerobic 
metabolism.
Objective marker of submaximal aerobic fitness/endurance. 
A VO2 at VAT between 40% and 60% VO2peak is considered 
normal
Peak respiratory 
exchange ratio 
(RER)
The ratio of ventilated CO2 to O2 averaged 
over the last 30 s of CPET
Reported in arbitrary units
In conjunction with the attainment of one other marker of 
peak performance, RER of >1.10 is indicative of a ‘peak’ 
effort during CPET
VE/VCO2 slope The linear slope relationship between VCO2 
(X-axis) and VE (Y-axis) throughout the entire 
CPET
Reported in arbitrary units
Index of ventilatory efficiency representing the matching of 
ventilation and perfusion of the lungs and heart, respectively, 
as well as peripheral chemoreceptor sensitivity
Slope >34 suggest poor prognosis
Oxygen uptake 
efficiency slope
The slope relationship between the 
logarithmically transformed minute ventilation 
(X-axis) and VO2 (Y-axis) throughout the entire 
CPET
Reported in arbitrary units
Index of ventilatory efficiency with strong correlation to 
VO2peak
Slope <1.4 considered to indicate poor prognosis
High accuracy even when exercise tests are not maximal
Oxygen uptake 
efficiency plateau
(OUEP)
The highest plateau in VO2 in relation to VE. 
Reported as the highest consecutive values 
of VO2/VE over 90 s.
Indicates the efficiency of oxygen uptake and global 
cardiovascular function
Can be used to profile severity of CHD and CHF with mean 
plateau values of 20–30 (VO2/VE mL/L) for CHF phenotypes
Low OUEP (<65% predicted) prognostic
Oxygen pulse
(O2/HR)
The ratio of VO2 to HR (O2/HR)
Values can be reported at a single point in 
time, for example, peak O2/HR averaged over 
15 s, or plotted to demonstrate a response 
across an entire CPET
Indirect measure of stroke volume response to exercise
O2/HR plateau or reduction despite increases work rates, 
especially a lower-to-moderate work rates may indicate 
falling stroke volume and possible myocardial ischaemia/
myocardial wall motion abnormality.
Low O2 pulse (<85% predicted) and early plateau/reduction in 
O2 pulse indicate poorer prognosis
CHD, coronary heart disease; CHF, chronic heart failure; CPET, cardiopulmonary exercise testing; DXA, dual X-ray absorptiometry; 
VE, minute ventilation; VO2peak,  peak oxygen uptake; VCO2,  carbon doxide elimination; VO2, oxygen uptake. 
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Panasonic Biomedical Sales Europe BV, Leicestershire, 
UK). This system has low measurement variability in 
healthy and cardiac populations when investigations are 
conducted by experienced and inexperienced operator’s 
alike.34 53 C-IMT will be assessed using previously outlined 
methods.34 Briefly, the CHS is equipped with a broadband 
probe (5–13 MHz) with a centre frequency optimised for 
carotid imaging. When correctly positioned over the CCA, 
automated integrated software locates the vessel’s far wall 
using a region of interest tool. The CHS automatically 
captures a sequence of images at end-diastole by moni-
toring vessel distension characteristics and ‘freezes’ when 
predefined C-IMT boundary quality criteria are met. 
Multiple measurements taken from a 1 cm segment of the 
CCA located 1 cm proximally from the carotid bifurca-
tion will be obtained. C-IMT will be measured at the right 
anterior (150°), lateral (120°) and posterior (90°) aspects 
and on the left anterior (210°), lateral (230°) and poste-
rior (270°) aspects. Mean and maximum (max) IMT will 
be recorded to three decimal places. Image quality will 
be manually inspected and trace lines modified where 
required. To enhance measurement reproducibility, the 
probe is equipped with an accelerometer and gyroscope 
that tracks the angle (˚) of insonation relative to ground. 
Each C-IMT measurement is recorded with the angle that 
the image was taken.
blood samples
Blood samples will be drawn and placed in a refriger-
ated (4°C) centrifuge at 3000 revolutions per minute, 
for 15 min. Routine testing will include full blood cell 
count, total cholesterol, estimated LDL cholesterol, 
HDL cholesterol, Triglycerides, kidney (eGFR) and liver 
function tests, non-fasting glucose and NT-proBNP. Addi-
tional blood serum and plasma samples will be stored in a 
−80°C freezer for future analysis of current and emerging 
biochemical markers of cardiovascular and metabolic 
health.
Estimated all-cause mortality
A 5-year risk of all-cause mortality will be calculated for 
each patient using the CALIBER 5-year prognostic risk 
score for stable CHD phenotypes (https://www. ucl. ac. 
uk/ health- informatics/ caliber).40 The CALIBER risk 
assessment model includes sociodemographics, CVD 
diagnosis and severity, CVD and non-CVD comorbidities, 
primary risk factors, psychosocial risk factors and plasma 
biomarkers.
Cr exercise intervention
Patients in the TG will undergo a routine 8-week 
(two times weekly, 16 sessions) CR exercise programme. 
A physiotherapist will conduct a one-to-one assessment 
before each patient commences exercise training. A 
personal exercise prescription will be developed for 
each individual. Patients will be asked to self-monitor 
exercise intensity and be encouraged to maintain a HR 
corresponding to 40%–70% of their predicted heart rate 
reserve (HRR) or an exercise ‘effort’ between ‘light’ and 
‘somewhat hard’ (11–14) on Borg’s rating of perceived 
exertion.54 Estimated training zones will be calculated 
using the Karvonen formula:
 ((206− (0.7× age))− resting heart rate (−30 if taking beta-blockers). 
Heart rate will be monitored with a Polar heart rate 
monitor. HR and RPE will be recorded at the end of each 
CV exercise station. This conforms to the recommenda-
tions of the Association of Chartered Physiotherapists in 
Cardiac Rehabilitation55 and the British Association of 
Cardiac Prevention and Rehabilitation56 57 (ie, >20-min 
aerobic exercise at 40%–70% HRR). An example list of CV 
and active recovery (AR) exercises are displayed in table 3.
Each exercise circuit will consist of a structured eight or 
nine station programme incorporating CV and AR exer-
cises. CV exercises will initially be prescribed for approx-
imately 1–2 min duration and up-titrated for each session 
depending on HR and RPE responses. The target CV exer-
cise duration for each session will be 20 min although CV 
exercise duration may be less than this in the first instance.
statistical analysis
The primary endpoint for statistical analysis is the mean 
change in VO2peak (mL/kg/min) from visit 1 to visit 2. For 
statistical purposes, visit 3 will be treated as a follow-up. 
This will establish the initial effect of the 8-week exercise 
intervention and any effects that it may have on CRF and 
cardiometabolic health over the 12-month study period. 
A main effect and an interaction effect for VO2peak will be 
investigated using a general linear model (parametric 
approach). The number of patients achieving a VO2peak 
improvement greater than 0.5 and 1.5 METs will also 
be reported.24 26 These values correspond to improve-
ments in CRF resulting from UK and international CR, 
respectively. Changes in other CRF variables will be 
discussed within the context of clinically meaningful 
thresholds (table 2) Baseline VO2peak, age and the cate-
gorical covariate, gender will be entered as covariates 
in exploratory analysis. Significant differences in group 
characteristics identified at baseline will also be treated 
as covariates. Secondary outcome measures, including 
C-IMT, and both maximal and submaximal CRF fitness 
Table 3 Example cardiovascular and active recovery 
exercises
Cardiovascular circuit 
exercises
Active recovery 
exercises
Box stepping Arm curls
Static cycling Sit to stand
Treadmill walking Wall press-up
Concept II rower Leg curls
Marching on the spot Lateral arm raises
Knee raises Trunk rotation
Half stars
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measures will be evaluated using the same approaches 
and covariates as the primary outcome analysis. Contin-
uous measures of exercise dose will be used to predict 
changes to peak VO2peak and other CPET variables.
Data will be entered into SPSS by a single investigator 
who will maintain overall responsibility for data quality. 
The primary and secondary outcome analyses will be 
conducted at the conventional (two-sided) 5% alpha level. 
Where parametric data distribution allows, partial eta 
squared values will also be reported. To reduce the risk of 
false-positive claims, secondary analyses will be considered 
exploratory if non-significant results are obtained from 
the primary analysis. All analyses will be performed on an 
intention-to-treat basis. Analysis carrying the last observed 
values forward (baseline or 3-month outcomes) will be 
performed for patients lost to follow-up. A per protocol 
analysis will also be conducted. Patients completing at 
least 14 (out of 16) exercise sessions will be classed as 
having completed CR. No timeframe for completion will 
be imposed, as CR is typically extended to incorporate 
any missed exercise sessions. All data will be summarised 
and reported in accordance with the Consolidated Stan-
dards of Reporting Trials guideline.48
Power analysis, performed in G-Power58 showed that 203 
patients (total) would be needed to attain statistical signif-
icance between the two groups. This was based on an esti-
mated post-intervention between group (TG compared 
with CG) VO2peak difference of 2 mL/kg/min with a pooled 
SD of 4 mL/kg/min/. A 2 mL/kg/min difference was 
selected based on a predicted 0.52 MET (mL/kg/min) 
CRF increase recently reported in UK CR programmes.24 A 
power of 90% and a group allocation ratio of 70% TG (123 
participants) to 30% CG (80 participants) with a predicted 
study attrition rate of 15% were applied. The assumption 
of uneven group sizes was made based on a local audit 
reporting that more patients participate in structured exer-
cise than decline (TG 57%; CG 43%).
Approximately 440 patients attend the local nurse-led 
CR clinic each year. With a recruitment rate of 10%, (44 
patients per year) the study duration is estimated to be 
5 years. The first patient was recruited in March 2014 
and recruitment is ongoing. The study is expected to 
complete in March 2019. A formal interim analysis59 on 
the primary and secondary outcomes will be conducted 
when 70 patients have completed the study (one-third of 
the cohort required on the a priori determined sample 
size). A decision on trial progression will be collectively 
made by the research team (estimated to be January 
2018). A data monitoring committee will not be used 
owing to the observational nature of the study.
Cr exercise prescription analysis
Recent evidence11 suggests that no single exercise compo-
nent within CR is predictive of mortality outcomes. 
However, reductions in both total and cardiovascular 
mortality were reported in trials which reported high levels 
of participant exercise adherence compared with those 
recording lower levels.11 Patients’  exercise doses have also 
been related to long-term survival outcomes.60 Accordingly, 
all exercise training characteristics, including adherence 
to the programme, will be recorded. CV exercise duration 
achieved by each patient at each of their 16 CR sessions 
will be calculated and summed to report a total exercise 
training duration. To characterise exercise intensity during 
each exercise session, the mean of patients’ HR following 
completion of all CV exercises for each session will be 
calculated. Patients’ ‘mean peak HR’ for each exercise 
session will be pooled for analysis. A ‘median of the mean’ 
HR will be reported. ‘Median peak HR’ will expressed as 
a percentage of the VAT determined from visit 1 CPET 
and relative to HRR obtained from visit 1 CPET. A simple 
composite score of intensity and CV exercise duration for 
each training session will be calculated and summed to 
provide an overall ‘exercise dose’ for each participant. The 
composite score will be:
 Mean peak HR
Patients′ CPET HRR×CV exercise duration . 
As an additional marker of exercise intensity the mean 
of a patient’s RPE following completion of an exer-
cise session will be calculated (mean RPE). As with HR, 
patient’s RPE scores for each exercise session will be 
pooled for analysis.
dissemination and impact
It is anticipated that throughout the trial, the experi-
ences gained will be presented at national conferences 
and non-academic outlets such as national governing 
body publications. On completion, the study results will 
be published in peer-reviewed journals and presented at 
scientific meetings.
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